Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Dumaz

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Oncotarget|July 25, 2016
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activationAndrelou F Vallarelli, P Sivaramakrishna Rachakonda, Jocelyne André, et al.
Cancer Research|October 5, 2006
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signalingNicolas Dumaz, Robert Hayward, Jan Martin, et al.
The Journal of Investigative Dermatology|February 9, 2016
Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell CarcinomaCharles Cassius, Cécile Pages, Jennifer Roux, et al.
Cancer Immunology, Immunotherapy : CII|April 16, 2022
The soluble form of CD160 acts as a tumor mediator of immune escape in melanomaMarie-Léa Gauci, Jérôme Giustiniani, Clémence Lepelletier, et al.
Human Molecular Genetics|October 11, 2017
Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3Claire Briet, Arrate Pereda, Catherine Le Stunff, et al.
Cancers|June 10, 2023
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In VitroJulie Delyon, Anaïs Vallet, Mélanie Bernard-Cacciarella, et al.
Cancers|April 30, 2020
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated MelanomaPauline Tétu, Julie Delyon, Jocelyne André, et al.
Plos One|April 21, 2010
Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genesClaude Lalou, Nathalie Scamuffa, Samia Mourah, et al.
The Journal of Investigative Dermatology|December 10, 2013
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinibMaryline Allegra, Damien Giacchero, Coralie Segalen, et al.
Oncogene|February 26, 2022
Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interactionAlexandra Landras, Coralie Reger de Moura, Bruno O Villoutreix, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Oncotarget|July 25, 2016
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activationAndrelou F Vallarelli, P Sivaramakrishna Rachakonda, Jocelyne André, et al.
Cancer Research|October 5, 2006
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signalingNicolas Dumaz, Robert Hayward, Jan Martin, et al.
The Journal of Investigative Dermatology|February 9, 2016
Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell CarcinomaCharles Cassius, Cécile Pages, Jennifer Roux, et al.
Cancer Immunology, Immunotherapy : CII|April 16, 2022
The soluble form of CD160 acts as a tumor mediator of immune escape in melanomaMarie-Léa Gauci, Jérôme Giustiniani, Clémence Lepelletier, et al.
Human Molecular Genetics|October 11, 2017
Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3Claire Briet, Arrate Pereda, Catherine Le Stunff, et al.
Cancers|June 10, 2023
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In VitroJulie Delyon, Anaïs Vallet, Mélanie Bernard-Cacciarella, et al.
Cancers|April 30, 2020
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated MelanomaPauline Tétu, Julie Delyon, Jocelyne André, et al.
Plos One|April 21, 2010
Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genesClaude Lalou, Nathalie Scamuffa, Samia Mourah, et al.
The Journal of Investigative Dermatology|December 10, 2013
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinibMaryline Allegra, Damien Giacchero, Coralie Segalen, et al.
Oncogene|February 26, 2022
Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interactionAlexandra Landras, Coralie Reger de Moura, Bruno O Villoutreix, et al.
Pageof 5